research Alopecia areata treatment with baricitinib: different relapse phenotypes
Baricitinib can lead to hair regrowth in alopecia areata but may also cause relapses.
Search
for
Did you mean Relapse?
Sort by
Research
30 / 1000+ resultsresearch Relapse of alopecia areata during ongoing Janus kinase inhibitor therapy is not uncommon and usually occurs in previously affected areas: A multicenter Italian real-world study
This abstract does not report results but indicates that the supplementary material includes comprehensive methodology, additional results, statistical analyses, discussion, and limitations of the Alopecia Areata Relapse Study Group's findings as presented in the main manuscript.
research Relapse of hirsutism following long‐term successful treatment with oestrogen–progestogen combination
This study found that while ethinyl oestradiol and cyproterone acetate effectively treated hirsutism in 90% of patients, 80% experienced relapse within six months after stopping treatment, suggesting long-term use is necessary.
research Relapse of Alopecia Areata Responders After Tofacitinib Withdrawal: A Retrospective Study of 59 Patients
Many patients with alopecia areata relapse after stopping tofacitinib.
research Clinical Profile and Predictors of Relapse in Patients with Alopecia Areata: A Follow-Up Study
This study found that a high proportion of alopecia areata patients experienced a relapse, typically within one year, with more extensive initial scalp involvement predicting an earlier return of the disease.
research Longitudinal clinical course, treatment outcomes, and relapse patterns in alopecia areata: a prospective cohort study
In this prospective cohort, baseline severity, disease activity, and relapse history were identified as key factors influencing response and recurrence in alopecia areata, suggesting that implementing standardized assessments could enhance risk stratification and personalized care approaches.
research Relapse in Alopecia Totalis after Successful Treatment with Intralesional Corticosteroid and Oral Immunomodulator
This case report describes a 19-year-old female with recurrent alopecia totalis who experienced complete remission after re-treatment with various therapies, emphasizing the importance of long-term follow-up in managing alopecia areata.
research Refractory/relapse thrombocytopenia in a patient with Evans' syndrome successfully treated with zanubrutinib
This study reports the first successful use of zanubrutinib to treat a 15-year-old Chinese girl with severe refractory Evans' syndrome, resulting in a sustained recovery of platelet counts and haemoglobin levels.
research A Case of Relapsed Leprosy Successfully Treated With Sparfloxacin
This case report describes a 29-year-old Japanese-Paraguayan man who experienced a relapse of leprosy 14 years after initial treatment, presenting with severe pain and skin lesions but no sensory impairment.
research Nonalimental Scurvy With Relapse Symptoms After Stopping Oral Vitamin C Supplementation
This case report describes a previously healthy 3-year-old girl who developed scurvy symptoms not directly linked to vitamin C dietary deficiency, highlighting the potential for misdiagnosis in similar cases.
research Hair Dye as a Potential Trigger for Relapse of Anti-GBM Disease: A Case Report
In this case study, a 43-year-old male with anti-GBM disease experienced a relapse triggered by hair dye, leading to diffuse alveolar hemorrhage; managing this with plasmapheresis, intravenous immunoglobulins, and rituximab suggests rituximab may be beneficial for relapsing cases.
research Arsenic Trioxide as Effective Therapy for Relapsed Acute Promyelocytic Leukemia
This article discusses arsenic trioxide as a treatment for refractory or relapsed acute promyelocytic leukemia, noting its effectiveness and manageable side effects.
research Sweet Syndrome as the Presenting Symptom of Relapsed Hairy Cell Leukemia
This case report describes a 49-year-old woman with Sweet syndrome who experienced complete resolution of skin lesions after a prednisone treatment regimen.
research Allergen desensitization reduces the severity of relapsed alopecia areata in dust‐mite allergic patients
This study found that adding allergen immunotherapy to conventional treatment may reduce relapse-related hair loss in house dust mite-allergic alopecia areata patients over a 3-year period.
research Considerations for the Treatment Strategy of Relapse After Tofacitinib Therapy in Alopecia Areata
In this study, authors present a case where a 26-year-old patient with alopecia areata experienced relapse after initially responding to Tofacitinib, mitigated by corticosteroids, highlighting challenges and potential insights into the treatment and pathogenesis of the condition.
research 04094 Quality of care and risk of relapse in porphyria cutanea tarda: a study from the Norwegian porphyria registry
In this study, Norwegian researchers followed over 350 patients with porphyria cutanea tarda for an average of 7 years and found that 25% experienced biochemical relapse, suggesting the importance of routine follow-up for early detection and management.
research New insights into the phenomenon of remissions and relapses in autoimmune diseases and the puzzle of benign autoantibodies in healthy individuals
This paper discusses the balance between target tissue destruction and recovery rates in autoimmune diseases, proposing that high recovery rates are crucial for remitting-relapsing patterns, while exercise might not be neuroprotective in secondary progressive multiple sclerosis.
research Vitiligo and Alopecia Areata After Donor Lymphocyte Infusions in a Child With Relapsed Acute Myeloid Leukemia
In this case study, donor lymphocyte infusions effectively eradicated measurable residual disease in a patient with relapsed acute myeloid leukemia after hematopoietic cell transplantation, while side effects included the development of vitiligo and alopecia areata, likely due to chronic graft-versus-host disease.
research A slow-cycling LGR5 tumour population mediates basal cell carcinoma relapse after therapy
This study found that vismodegib promotes Basal cell carcinoma regression by inducing tumor differentiation but leaves a small population of quiescent cells that can drive relapse, which can be eliminated by adding a Wnt signaling inhibitor.
research Diphenylcyclopropenone in severe alopecia areata in children and adolescents: long-term follow-up and relapse rate
This study suggests that DPCP treatment can be effective and safe for severe alopecia areata in children, with maintenance therapy potentially reducing relapse rates.
research A Comparison of the Efficacy, Relapse Rate and Side Effects among Three Modalities of Systemic Corticosteroid Therapy for Alopecia Areata
This study found that intramuscular triamcinolone acetonide or pulse therapy effectively treats alopecia areata with manageable side effects, but further strategies are needed to reduce relapse rates.
research Nature-skin-based multi-responsive controlled-release electroactive scaffolds for integrated melanoma postoperative relapse prevention and wound therapy
In this study, a newly engineered scaffold, PADM-MX-Ag-Si@Dox, demonstrated potential as a multifunctional biomaterial for postoperative melanoma treatment by controlling drug release, enhancing wound healing, and enabling real-time tumor surveillance through temperature, pH, and electrical stimuli.
research A Follicle‐Targeting Dual Anti‐Fungal and Immunomodulatory Platform Against Fungal Invasion and Relapse Prevention
This study found that theabrownin-selenium nanoparticles (TB-Se NPs) effectively target Malassezia-induced dermatitis through a dual antifungal and immunomodulatory mechanism, suppressing fungal overgrowth, reducing inflammation, and enhancing immune memory to prevent recurrence in a dermatitis model.
research Post-COVID-19 Alopecia Universalis: Autoimmune Hair Loss and the Challenge of Relapse Management.
This case report describes a 79-year-old woman who developed alopecia universalis shortly after recovering from COVID-19, highlighting its relapsing nature and the challenges in long-term disease management.
research A Comparison of the Efficacy, Relapse Rate and Side Effects among Three Modalities of Systemic Corticosteroid Therapy for Alopecia Areata
Intramuscular triamcinolone and pulse therapy with oral predonine are effective for alopecia areata with manageable side effects, but better relapse prevention is needed.
research Table 1_Longitudinal clinical course, treatment outcomes, and relapse patterns in alopecia areata: a prospective cohort study.docx
In this prospective cohort study, 62.5% of alopecia areata patients achieved significant hair regrowth by week 24, but 31.8% experienced relapses by week 52, with baseline severity and disease activity influencing outcomes and quality of life improving significantly over the study period.
research Mitoxantrone, Etoposide and Prednisolone—a Novel Combination in The Treatment of Relapsed and Refractory Lymphoma
This study reported a 74% overall response rate for a new combination chemotherapy of mitoxantrone, etoposide, and prednisolone in patients with relapsed or refractory Hodgkin's disease or non-Hodgkin's lymphoma.
research Accurate quantification of minimal residual disease at day 15, by real-time quantitative polymerase chain reaction identifies also patients with B-precursor acute lymphoblastic leukemia at high risk for relapse
This article discusses the evaluation of minimal residual disease in childhood acute lymphoblastic leukemia using molecular methods and reports no new findings.
research Bimatoprost versus Mometasone Furoate in the Treatment of Scalp Alopecia Areata: A Pilot Study
In this study, bimatoprost solution showed better results than corticosteroid in terms of rapidity, percentage of hair regrowth, and side effects for treating scalp alopecia areata.
research Alopecia areata: a long‐term follow‐up study of 104 patients
This study found that the severity, duration, and relapse rate of alopecia areata decreased with older age at onset, while relapses mostly occurred early and declined over time.